Summary
Globally, over 237 million people suffer from peripheral artery disease (PAD), an abnormal narrowing of the arteries. The implantation of stents (spiral wire protheses) is the first-line therapy for PAD with ~ 3.5M stents implanted worldwide every year. Restenosis, the gradual reclogging
of the blood vessel after stent implantation, is a major problem leading to high morbidity and mortality which occurs within 6 years after implantation in ~23 % of all cases and is often detected when it is too late. More frequent surveillance of PAD patients to avoid unnecessary amputations
and death is an unmet clinical challenge. VesselSens is developing the StentGuard, a smart therapeutic monitoring device that enables rapid, low cost, early diagnosis of restenosis non-invasively and reliably. This device allows stent monitoring at high frequencies with low cost by
non-specialist medical practitioners solving the problem of unchecked disease progression and saving the EU economy over €1bn/ year.
of the blood vessel after stent implantation, is a major problem leading to high morbidity and mortality which occurs within 6 years after implantation in ~23 % of all cases and is often detected when it is too late. More frequent surveillance of PAD patients to avoid unnecessary amputations
and death is an unmet clinical challenge. VesselSens is developing the StentGuard, a smart therapeutic monitoring device that enables rapid, low cost, early diagnosis of restenosis non-invasively and reliably. This device allows stent monitoring at high frequencies with low cost by
non-specialist medical practitioners solving the problem of unchecked disease progression and saving the EU economy over €1bn/ year.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190107486 |
| Start date: | 01-10-2022 |
| End date: | 31-07-2025 |
| Total budget - Public funding: | 11 306 517,50 Euro - 2 500 000,00 Euro |
Cordis data
Original description
Globally, over 237 million people suffer from peripheral artery disease (PAD), an abnormal narrowing of the arteries. The implantation of stents (spiral wire protheses) is the first-line therapy for PAD with ~ 3.5M stents implanted worldwide every year. Restenosis, the gradual recloggingof the blood vessel after stent implantation, is a major problem leading to high morbidity and mortality which occurs within 6 years after implantation in ~23 % of all cases and is often detected when it is too late. More frequent surveillance of PAD patients to avoid unnecessary amputations
and death is an unmet clinical challenge. VesselSens is developing the StentGuard, a smart therapeutic monitoring device that enables rapid, low cost, early diagnosis of restenosis non-invasively and reliably. This device allows stent monitoring at high frequencies with low cost by
non-specialist medical practitioners solving the problem of unchecked disease progression and saving the EU economy over €1bn/ year.
Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
09-02-2023
Geographical location(s)
